Hemogenyx Pharmaceuticals PLC Cash Flow Conversion Efficiency
Hemogenyx Pharmaceuticals PLC cash flow conversion efficiency. Based on the latest financial reports, Hemogenyx Pharmaceuticals PLC (HEMO) has a cash flow conversion efficiency ratio of -2.090x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-1.78 Million ≈ $-216.99 USD) by net assets (GBX853.49K ≈ $103.85 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Hemogenyx Pharmaceuticals PLC (2015–2024)
Cash flow conversion efficiency of Hemogenyx Pharmaceuticals PLC from 2015 to 2024. This chart illustrates how Hemogenyx Pharmaceuticals PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View HEMO live share price for real-time trading data and today's change.
Hemogenyx Pharmaceuticals PLC Cash Flow Conversion Ratio Explained
Hemogenyx Pharmaceuticals PLC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Hemogenyx Pharmaceuticals PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hemogenyx Pharmaceuticals PLC ranked by their cash flow conversion efficiency. Also see how much is Hemogenyx Pharmaceuticals PLC worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ALBERT LABS INTL. CORP.
F:VB50
|
N/A |
|
SU Group Holdings Limited Ordinary Shares
NASDAQ:SUGP
|
-0.057x |
|
PROPHECY DEFI INC.
F:V8M
|
N/A |
|
Global Gas Corporation
NASDAQ:HGAS
|
0.072x |
|
LIVE MOTION GAMES ZY -10
F:4YM
|
0.873x |
|
Metgasco Ltd
AU:MEL
|
0.075x |
|
SysGroup PLC
LSE:SYS
|
0.029x |
|
Nevada Zinc Corp
V:NZN
|
0.109x |
Annual Cash Flow Conversion Efficiency for Hemogenyx Pharmaceuticals PLC (2015–2024)
The table below shows the annual cash flow conversion efficiency of Hemogenyx Pharmaceuticals PLC from 2015 to 2024. Review cash generation quality of Hemogenyx Pharmaceuticals PLC to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX853.49K ≈ $103.85 |
GBX-4.12 Million ≈ $-500.91 |
-4.824x | -119.71% |
| 2023-12-31 | GBX2.78 Million ≈ $338.37 |
GBX-6.11 Million ≈ $-742.87 |
-2.195x | -144.66% |
| 2022-12-31 | GBX3.24 Million ≈ $394.64 |
GBX-2.91 Million ≈ $-354.14 |
-0.897x | -178.97% |
| 2021-12-31 | GBX8.17 Million ≈ $993.76 |
GBX-2.63 Million ≈ $-319.67 |
-0.322x | +84.34% |
| 2020-12-31 | GBX875.68K ≈ $106.55 |
GBX-1.80 Million ≈ $-218.81 |
-2.054x | -159.74% |
| 2019-12-31 | GBX-349.04K ≈ $-42.47 |
GBX-1.20 Million ≈ $-145.99 |
3.438x | +343.75% |
| 2018-12-31 | GBX959.17K ≈ $116.70 |
GBX-1.35 Million ≈ $-164.59 |
-1.410x | -563.74% |
| 2017-12-31 | GBX2.13 Million ≈ $259.39 |
GBX-452.98K ≈ $-55.11 |
-0.212x | +30.96% |
| 2016-12-31 | GBX903.71K ≈ $109.96 |
GBX-278.15K ≈ $-33.84 |
-0.308x | -30148.52% |
| 2015-12-31 | GBX77.82K ≈ $9.47 |
GBX79.71 ≈ $0.01 |
0.001x | -- |
About Hemogenyx Pharmaceuticals PLC
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer. The company's lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurol… Read more